MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX GrowthMarketBeat · 5 days ago
This MannKind Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For MondayBenzinga · Oct 19, 2026
MannKind to Participate in the Chardan Healthcare ConferenceGlobeNewsWire · Oct 14, 2026
MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)Globe News Wire · Oct 9, 2026
MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains MomentumMarketBeat · Sep 17, 2026
Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management MoleculeBenzinga · Sep 9, 2026MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | -$0.01 | -$0.06 | Miss |
| May 6, 2026 | -$0.02 | -$0.05 | Miss |
| Feb 26, 2026 | -$0.01 | -$0.05 | Miss |
| Nov 5, 2025 | $0.01 | $0.03 | Beat |
| Aug 6, 2025 | $0.04 | $0.00 | Miss |
| May 8, 2025 | $0.03 | $0.04 | Beat |